BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28483373)

  • 21. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
    Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
    Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.
    Ujjani CS; Hill EM; Wang H; Nassif S; Esposito G; Ozdemirli M; Cordova C; Cheson BD
    Br J Haematol; 2016 Aug; 174(3):410-6. PubMed ID: 27098364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. End-of-treatment
    Allioux F; Gandhi D; Vilque JP; Nganoa C; Gac AC; Aide N; Lasnon C
    Leuk Lymphoma; 2021 Dec; 62(12):2890-2898. PubMed ID: 34219589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
    Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
    Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
    Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
    Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
    Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
    Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interim FDG-PET/CT for Response Assessment of Lymphoma.
    Zeman MN; Akin EA; Merryman RW; Jacene HA
    Semin Nucl Med; 2023 May; 53(3):371-388. PubMed ID: 36376131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
    Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
    Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
    Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].
    Wang RM; Li F; Liu CB; Guan ZW; Fu LP; Xu BX; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):74-79. PubMed ID: 30738450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
    Terasawa T; Lau J; Bardet S; Couturier O; Hotta T; Hutchings M; Nihashi T; Nagai H
    J Clin Oncol; 2009 Apr; 27(11):1906-14. PubMed ID: 19273713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.
    Okada Y; Nihashi T; Fujii M; Kato K; Okochi Y; Ando Y; Yamashita M; Maesawa S; Takebayashi S; Wakabayashi T; Naganawa S
    Clin Nucl Med; 2012 Sep; 37(9):843-9. PubMed ID: 22889772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
    Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG
    Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different predictive values of interim
    Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
    Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basal (18)F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment.
    Jiménez Londoño GA; García Vicente AM; Poblete García VM; Amo-Salas M; Calle Primo C; Ibañez García Á; Martínez Sanchís B; López-Fidalgo JF; Solano Ramos F; Martínez Hellín A; Díaz Morfa M; Soriano Castrejón Á
    Rev Esp Med Nucl Imagen Mol; 2016; 35(5):298-305. PubMed ID: 27312693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are Semiquantitative Methods Superior to Deauville Scoring in the Monitoring Therapy Response for Pediatric Hodgkin Lymphoma?
    Ibrahim F; Gabelloni M; Faggioni L; Padma S; Visakh AR; Cioni D; Neri E
    J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim PET in Diffuse Large B-Cell Lymphoma.
    Kurch L; Hüttmann A; Georgi TW; Rekowski J; Sabri O; Schmitz C; Kluge R; Dührsen U; Hasenclever D
    J Nucl Med; 2021 Aug; 62(8):1068-1074. PubMed ID: 33246974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.